Capital Fund Management S.A. Regeneron Pharmaceuticals, Inc. Transaction History

Capital Fund Management S.A.

$36 Billion
Q3 2024

A detailed history of Capital Fund Management S.A. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Fund Management S.A. holds 16,882 shares of REGN stock, worth $12 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

16,882

Previous 11,851 42.45%

Holding current value

$12 Million

Previous $12.5 Million 42.49%

% of portfolio

0.05%

Previous 0.04%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1024.09 - $1201.76 $5.15 Million - $6.05 Million	5,031 Added 42.45%	16,882 $17.7 Million
Q2 2024 Aug 13, 2024	SELL	$883.2 - $1071.19 $1.85 Million - $2.25 Million	-2,096 Reduced 15.03%	11,851 $12.5 Million
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $12.6 Million - $13.9 Million	13,947 New	13,947 $13.4 Million
Q2 2022 Aug 12, 2022	BUY	$548.35 - $738.84 $13.7 Million - $18.5 Million	25,054 New	25,054 $14.8 Million
Q4 2021 Feb 10, 2022	SELL	$543.48 - $670.97 $6.37 Million - $7.87 Million	-11,722 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$574.03 - $680.96 $2.82 Million - $3.34 Million	-4,908 Reduced 29.51%	11,722 $7.09 Million
Q2 2021 Aug 12, 2021	SELL	$472.8 - $558.54 $4.25 Million - $5.02 Million	-8,988 Reduced 35.08%	16,630 $9.29 Million
Q2 2019 Aug 12, 2019	BUY	$299.6 - $414.82 $6.64 Million - $9.2 Million	22,171 Added 643.2%	25,618 $8.02 Million
Q1 2019 May 13, 2019	BUY	$372.08 - $439.57 $1.28 Million - $1.52 Million	3,447 New	3,447 $1.42 Million

Others Institutions Holding REGN

# of Institutions

1,484

Shares Held

83.7M

Call Options Held

1.22M

Put Options Held

1.5M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.

Account

Capital Fund Management S.A. Regeneron Pharmaceuticals, Inc. Transaction History